Inter-and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors

Annals of Oncology

Volumn 21, Issue 8, 2010, Pages 1682-1686

  Barlesi F ^a   Balleyguier, C ^b   Besse, B ^b   Bonodeau, F ^c   Brenac, F ^d   Corneloup, O ^e   Dansin, E ^c   Ferretti, G ^f   Gaubert, J Y ^a   Gervais, R ^d   Lacombe, C ^g   Loundou, A ^a   Moro Sibilot, D ^f   Planchard, D ^b   Scherpereel, A ^h   Menu, Y ^g  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CENTRE OSCAR LAMBRET   (France)

^d CENTRE FRANÇOIS BACLESSE   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f GRENOBLE UNIVERSITY HOSPITAL   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Antiangiogenic drugs; Bevacizumab; Consistency; CT scan; Non small cell lung cancer

Indexed keywords

BEVACIZUMAB;

ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CORRESPONDENCE ANALYSIS; HUMAN; INTERNAL CONSISTENCY; KAPPA STATISTICS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; OBSERVER VARIATION; PATIENT SELECTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TUMOR LOCALIZATION; TUMOR VASCULARIZATION;

EID: 77955246889     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp590     Document Type: Article

References (26)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
2. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
3. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
4. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
5. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191.
6. Herbst R. Toxicities of antiangiogenic therapy in non-small-cell lung cancer. Clin Lung Cancer 2006; 8: S23-S30.
7. Somer RA, Sherman E, Langer CJ. Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of ECOG4599. Clin Lung Cancer 2008; 9: 102-105.
8. Sandler AB, Johnson DH, Brahmer J et al. Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24: 49S (Abstr 7068).
9. Sandler AB, Hirsh V, Gray R et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. J Clin Oncol 2009; 27: 1405-1412.
10. Marom EM, Martinez CH, Truong MT et al. Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol 2008; 3: 351-357.
11. Crino L, Mezger J, Griesinger F et al. MO19390 (SAiL): safety and efficacy of first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27(15s): (Abstr 8043).
12. Fischbach NA, Spigel D, Brahmer J et al. Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: a bevacizumab (BV) treatment observational cohort study (OCS). J Clin Oncol 2009; 27(15s): (Abstr 8040).
13. Herman SJ, Winton TL, Weisbrod GL et al. Mediastinal invasion by bronchogenic carcinoma: CT signs. Radiology 1994; 190: 841-846.
14. Glazer HS, Kaiser LR, Anderson DJ et al. Indeterminate mediastinal invasion in bronchogenic carcinoma: CT evaluation. Radiology 1989; 173: 37-42.
15. Verschakelen JA, Bogaert J, De Wever W. Computed tomography in staging for lung cancer. Eur Respir J 2002; 35 (Suppl): 40s-48s.
16. Munden RF, Swisher SS, Stevens CW et al. Imaging of the patient with non-small cell lung cancer. Radiology 2005; 237: 803-818.
17. Dai LY, Jin WJ. Interobserver and intraobserver reliability in the load sharing classification of the assessment of thoracolumbar burst fractures. Spine 2005; 30: 354-358.
18. Landis JR, Koch GG. The measurement of observer agreement for caterogical data. Biometrics 1977; 33: 159-174.
19. Greenacre MJ. Theory and Application of Correspondence Analysis. London: Academic Press 1984.
20. Bouilland S, Loslever P. Multiple correspondence analysis of biomechanical signals characterized through fuzzy histograms. J Biomech 1998; 31: 663-666.
21. Panagiotakos DB, Pitsavos C. Interpretation of epidemiological data using multiple correspondence analysis and log-linear models. J Data Sci 2004; 2: 75-86.
22. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009; 27(8): 1227-1234.
23. Gierada DS, Pilgram TK, Ford M et al. Lung cancer: interobserver agreement on interpretation of pulmonary findings at low-dose CT screening. Radiology 2008; 246(1): 265-272.
24. Erasmus JJ, Gladish GW, Broemeling L et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 2003; 21: 2574-2582.
25. Higashino T, Ohno Y, Takenaka D et al. Thin-section multiplanar reformats from multidetector-row CT data: utility for assessment of regional tumor extent in non-small cell lung cancer. Eur J Radiol 2005; 56: 48-55.
26. Zhao B, James LP, Moskowitz CS et al. Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology 2009; 252(1): 263-272.